Site-directed RNA Editing to Modulate Kinase Activity as a Chemotherapeutic
通过定点 RNA 编辑调节激酶活性作为化疗药物
基本信息
- 批准号:10313239
- 负责人:
- 金额:$ 3.82万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-08-01 至 2022-07-31
- 项目状态:已结题
- 来源:
- 关键词:AdenosineAffectAntineoplastic AgentsApoptosisArginineBase PairingBiological AssayCell Culture TechniquesCell DeathCellsChemicalsClinicalCodon NucleotidesComplementary DNACrystallizationDNADRADA2b proteinDevelopmentDideoxy Chain Termination DNA SequencingDiseaseDoseDouble-Stranded RNADrug TargetingDrug resistanceEngineeringEnzymesFaceFamilyFluorescenceFluorescence MicroscopyGenetic DiseasesGlioblastomaGuanosineGuide RNAImmunizationIn VitroInosineLeadLysineMalignant NeoplasmsMeasuresMediatingMessenger RNAMethodsModificationMutationOligonucleotidesOncologyPathway interactionsPhosphoproteinsPhosphorylationPhosphotransferasesPrevalenceProtein AnalysisProtein KinaseProteinsRNARNA EditingReactionResearchResolutionRoentgen RaysSignal TransductionSignal Transduction PathwaySiteStructureTechniquesTerminator CodonTherapeuticTherapeutic UsesTimeTrainingTryptophanWestern BlottingWorkadenosine deaminaseanti-cancerbasecancer therapycell growthchemical synthesisdesignexperienceexperimental studyin vitro activityinhibitor/antagonistinterestkinase inhibitormutantnoveloverexpressionpreferenceprematureprogramsresponsesingle moleculesmall moleculesuccesstargeted delivery
项目摘要
PROJECT SUMMARY
The development of small molecules that target dysregulated protein kinases led to a paradigm shift in
the treatment of cancer. However, the need for novel methods of kinase inhibition is demonstrated by selectivity
challenges and the emergence of drug resistance. This proposal explores how RNA editing by Adenosine
Deaminase Acting on RNA (ADAR) enzymes can be used to modulate target protein activity in cancers, through
the optimization of guide oligonucleotides that promote editing in specific sequence contexts. The ADAR family
of enzymes converts adenosine to inosine in RNA, and can be directed to a target adenosine by a
complementary guide oligonucleotide. Thus far, the field of RNA editing by ADAR enzymes has focused on
correcting disease-causative premature termination codons, due to ADAR’s preference for editing adenosines
within a termination codon. However, lysine codons are known to be deaminated by ADARs, and are of particular
interest due to the presence of a conserved catalytic lysine residue in protein kinases. Reaction of the lysine
codon with ADAR2 would produce an arginine codon: a known inactivating mutation in protein kinases. To drive
editing at the catalytic lysine within kinase mRNA, an established rational design approach to guide
oligonucleotide chemical modifications will be used. Our strategy for site-directed RNA editing has high
therapeutic potential because it utilizes endogenous ADAR enzymes, and therefore only requires the delivery of
a guide oligonucleotide. While enzyme delivery faces barriers in efficiency and immune stimulation,
oligonucleotide therapies have had recent successes in targeted delivery. The central hypothesis of this project
is that guide oligonucleotide-directed editing of protein kinase mRNA will lead to a reduction in downstream cell
signaling in cancers. Aim 1 will define how guide RNA modifications affect editing of target adenosines in lysine
codons via oligonucleotide chemical synthesis, and in vitro activity assays. Aim 2 will evaluate the effect of protein
kinase mRNA editing on protein phosphorylation and apoptosis in glioblastoma cells. Training in cell culture,
Western blotting, and fluorescence microscopy will enable the cellular analysis of protein kinase mRNA editing.
This proof of principle experiment will have broad implications in cancer therapeutics by establishing the efficacy
of RNA editing to modulate disordered protein activity. More broadly this will expand the potential therapeutic
applications of ADAR editing by defining how guide RNAs can be engineered to act in non-preferred sequence
contexts.
项目总结
靶向失调的蛋白激酶的小分子的发展导致了
癌症的治疗。然而,选择性证明需要新的方法来抑制激酶。
挑战和抗药性的出现。这项提案探索了腺苷如何编辑RNA
作用于RNA(ADAR)酶的脱氨酶可用于调节癌症中的靶蛋白活性,通过
优化引导寡核苷酸,促进在特定序列背景下的编辑。阿达尔家族
的酶将腺苷转化为核糖核酸中的肌苷,并可通过一种
互补引导寡核苷酸。到目前为止,ADAR酶的RNA编辑领域一直专注于
由于ADAR对编辑腺苷的偏好,纠正致病的提前终止密码子
在终止密码子中。然而,已知赖氨酸密码子会被ADAR去氨基,并且具有特殊的
感兴趣的原因是蛋白激酶中存在保守的催化赖氨酸残基。赖氨酸的反应
带有ADAR2的密码子将产生精氨酸密码子:一种已知的蛋白激酶失活突变。开车
在激酶mRNA中编辑催化赖氨酸,一种既定的合理设计方法来指导
将使用寡核苷酸化学修饰。我们的站点定向RNA编辑策略很高
治疗潜力,因为它利用内源性ADAR酶,因此只需要传递
一种指导性寡核苷酸。虽然酶的传递在效率和免疫刺激方面面临障碍,
寡核苷酸疗法最近在靶向递送方面取得了成功。这个项目的中心假设是
引导寡核苷酸对蛋白激酶mRNA进行编辑将导致下游细胞减少
癌症的信号。目标1将定义指南RNA修饰如何影响赖氨酸中目标腺苷的编辑
通过寡核苷酸化学合成和体外活性测定。目标2将评估蛋白质的效果
蛋白激酶信使核糖核酸编辑对胶质母细胞瘤细胞蛋白磷酸化和细胞凋亡的影响。细胞培养方面的培训,
Western blotting和荧光显微镜将使细胞分析蛋白激酶mRNA编辑成为可能。
这项原则性实验的证明将通过确定疗效而在癌症治疗中产生广泛的影响。
RNA编辑来调节无序的蛋白质活性。更广泛地说,这将扩大潜在的治疗
ADAR编辑的应用,通过定义如何将引导RNA设计为以非首选顺序起作用
上下文。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Erin E Doherty其他文献
Poor Outcomes Among Pediatric Non-Down Syndrome Acute Megakaryocytic Leukemia Patients Irrespective of Receipt of Hematopoietic Stem Cell Transplant
- DOI:
10.1182/blood-2022-167487 - 发表时间:
2022-11-15 - 期刊:
- 影响因子:
- 作者:
Gabriela Llaurador;Matthew Willis;Michele Redell;M Monica Gramatges;Swati Naik;Robert A. Krance;Erin E Doherty;Alexandra McLean Stevens - 通讯作者:
Alexandra McLean Stevens
Erin E Doherty的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似海外基金
RII Track-4:NSF: From the Ground Up to the Air Above Coastal Dunes: How Groundwater and Evaporation Affect the Mechanism of Wind Erosion
RII Track-4:NSF:从地面到沿海沙丘上方的空气:地下水和蒸发如何影响风蚀机制
- 批准号:
2327346 - 财政年份:2024
- 资助金额:
$ 3.82万 - 项目类别:
Standard Grant
BRC-BIO: Establishing Astrangia poculata as a study system to understand how multi-partner symbiotic interactions affect pathogen response in cnidarians
BRC-BIO:建立 Astrangia poculata 作为研究系统,以了解多伙伴共生相互作用如何影响刺胞动物的病原体反应
- 批准号:
2312555 - 财政年份:2024
- 资助金额:
$ 3.82万 - 项目类别:
Standard Grant
How Does Particle Material Properties Insoluble and Partially Soluble Affect Sensory Perception Of Fat based Products
不溶性和部分可溶的颗粒材料特性如何影响脂肪基产品的感官知觉
- 批准号:
BB/Z514391/1 - 财政年份:2024
- 资助金额:
$ 3.82万 - 项目类别:
Training Grant
Graduating in Austerity: Do Welfare Cuts Affect the Career Path of University Students?
紧缩毕业:福利削减会影响大学生的职业道路吗?
- 批准号:
ES/Z502595/1 - 财政年份:2024
- 资助金额:
$ 3.82万 - 项目类别:
Fellowship
Insecure lives and the policy disconnect: How multiple insecurities affect Levelling Up and what joined-up policy can do to help
不安全的生活和政策脱节:多种不安全因素如何影响升级以及联合政策可以提供哪些帮助
- 批准号:
ES/Z000149/1 - 财政年份:2024
- 资助金额:
$ 3.82万 - 项目类别:
Research Grant
感性個人差指標 Affect-X の構築とビスポークAIサービスの基盤確立
建立个人敏感度指数 Affect-X 并为定制人工智能服务奠定基础
- 批准号:
23K24936 - 财政年份:2024
- 资助金额:
$ 3.82万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
How does metal binding affect the function of proteins targeted by a devastating pathogen of cereal crops?
金属结合如何影响谷类作物毁灭性病原体靶向的蛋白质的功能?
- 批准号:
2901648 - 财政年份:2024
- 资助金额:
$ 3.82万 - 项目类别:
Studentship
ERI: Developing a Trust-supporting Design Framework with Affect for Human-AI Collaboration
ERI:开发一个支持信任的设计框架,影响人类与人工智能的协作
- 批准号:
2301846 - 财政年份:2023
- 资助金额:
$ 3.82万 - 项目类别:
Standard Grant
Investigating how double-negative T cells affect anti-leukemic and GvHD-inducing activities of conventional T cells
研究双阴性 T 细胞如何影响传统 T 细胞的抗白血病和 GvHD 诱导活性
- 批准号:
488039 - 财政年份:2023
- 资助金额:
$ 3.82万 - 项目类别:
Operating Grants
How motor impairments due to neurodegenerative diseases affect masticatory movements
神经退行性疾病引起的运动障碍如何影响咀嚼运动
- 批准号:
23K16076 - 财政年份:2023
- 资助金额:
$ 3.82万 - 项目类别:
Grant-in-Aid for Early-Career Scientists














{{item.name}}会员




